This study retrospectively reviewed the pathological remission status of NAT for HER2-positive BC and compared the efficacy of HP and HPy targeted therapies combined with chemotherapy, yielding results similar to those of previous studies (27–30). This evidence concerns the gene BRD2 and breast cancer.